Effect of maraviroc on HIV disease progression-related biomarkers

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5858-5864

  Romero Sánchez, M Concepción ^a   Machmach, Kawthar ^a   Gonzalez Serna, Alejandro ^a   Genebat, Miguel ^a   Pulido, Ildefonso ^a   García García, María ^a   Álvarez Ríos, Ana Isabel ^a   Ferrando Martinez, Sara ^a   Ruiz Mateos, Ezequiel ^a,b   Leal, Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; CD14 ANTIGEN; D DIMER; MARAVIROC;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGING; CELLULAR DISTRIBUTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOHEXANES; DISEASE PROGRESSION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECEPTORS, CCR5; RNA, VIRAL; TRIAZOLES; VIRAL LOAD;

EID: 84868020168     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01406-12     Document Type: Article

References (25)

1. Asmuth DM, et al. 2010. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J. Acquir. Immune Defic. Syndr. 54:394-397.
2. Badley AD, et al. 1999. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ. 6:420-432.
3. Baker JV, et al. 2011. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 56:36 - 43.
4. Boulware DR, et al. 2011. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J. Infect. Dis. 203:1637-1646.
5. Bucy RP, et al. 1999. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J. Clin. Invest. 103:1391-1398.
6. Cao W, et al. 2009. Premature aging of T cells is associated with faster HIV-1 disease progression. J. Acquir. Immune Defic. Syndr. 50:137-147.
7. Dorr P, et al. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
8. Ferrando-Martinez S, Ruiz-Mateos E, Leal M. 2010. CD27 and CCR7 expression on naive T cells, are both necessary? Immunol. Lett. 127:157-158.
9. Franco JM, et al. 1999. Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis. 18:733-736.
10. Funderburg N, et al. 2010. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One 5:e13188. doi:10.1371/ journal.pone.0013188.
11. Genebat M, et al. 2009. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J. Antimicrob. Chemother. 64:845-849.
12. Giorgi JV, et al. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179:859-870.
13. Giorgi JV, et al. 1993. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J. Acquir. Immune Defic. Syndr. 6:904-912.
14. Gutierrez C, et al. 2011. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One 6:e27864. doi:10.1371/journal.pone.0027864.
15. Hazenberg MD, et al. 2000. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95:249-255.
16. Kuller LH, et al. 2008. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5:e203. doi:10.1371/ journal.pmed.0050203.
17. Liu Z, et al. 1997. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16: 83-92.
18. Palella FJ, Jr, et al. 2011. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS 25:1865-1876.
19. Palella FJ, Jr, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
20. Pulido I, et al. 2012. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. J. Infect. 64:417-423.
21. Rossi R, et al. 2010. Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J. Acquir. Immune Defic. Syndr. 54:e13-e14.
22. Ruiz-Mateos E, et al. 2011. Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors. Antimicrob. Agents Chemother. 55:4664 - 4669.
23. Saag M, et al. 2009. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J. Infect. Dis. 199:1638-1647.
24. Sandler NG, et al. 2011. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203:780-790.
25. Wilkin TJ, Ribaudo HR, Tenorio AR, Gulick RM. 2010. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin. Trials 11:351-358.